Osso VR Raises $66 Million

Osso VR, a validated virtual reality (VR) surgical training and assessment platform, today announced that it has secured $66 million in Series C funding led by Oak HC/FT. The round also includes participation from Signalfire, GSR Ventures, Tiger Global Management and Kaiser Permanente Ventures.

The capital will be used to accelerate Osso VR’s initiative to broaden access to surgical education for all healthcare professionals and continue the investment in hiring top-tier talent to bring high-fidelity surgical training experiences to additional specialty areas.
Osso VR produces on-demand, immersive modules that allow surgical teams to train independently or collaboratively in a virtual environment before ever stepping foot into a real operating room. Medical device companies also use Osso VR to introduce technology digitally, addressing many challenges of traditional educational pathways ⁠such as conflicting physician schedules, remote staff, and costly travel. With Osso VR, more surgeons can practice utilizing complex medical technologies to more rapidly offer their patients access to the best procedures with optimal outcomes.
“Oak HC/FT is continuously seeking new opportunities to support innovative companies impacting the healthcare industry in a meaningful way,” said Vig Chandramouli, Partner at Oak HC/FT. “Osso VR is well positioned to become the gold standard for all surgical training and continuing education, and we’re thrilled to work alongside this impassioned and committed team.”
Osso VR currently partners with leading global medical device companies, including Johnson & Johnson, Stryker, Zimmer Biomet, and Smith + Nephew. The company’s modules cover multiple specialty areas, such as orthopedics, spine, interventional cardiology, and general surgery, amongst others.
“The future at Osso VR is incredibly bright. Each step of the way, we’ve stayed true to our mission to democratize healthcare and seen the results that our platform brings to surgical training and  assessment,” said Justin Barad, MD, CEO and Co-Founder of Osso VR. “This round of investment supports the next step of our journey to provide access to all healthcare professionals. I couldn’t be more excited to take this next step with such a talented, passionate team.”
The company has more than 150 employees and plans to grow exponentially over the next year. Osso VR designs and develops all virtual experiences in-house and has hired talent across an array of industries, including healthcare, technology, movies and gaming. The company boasts the largest team of medical illustrators in the world.
The funding news comes on the heels of Osso VR winning the prestigious SXSW Innovation Award for VR, AR, and MR. The company is also exhibiting at the AAOS 2022 Annual Meeting this week in Chicago, Ill.
SourceOsso VR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”